Invasive serogroup B meningococci in England following three years of 4CMenB vaccination – First real-world data - 14/02/22
, Xilian Bai a, Aiswarya Lekshmi a, Stephen A. Clark a, Laura Willerton a, Sonia Ribeiro b, Helen Campbell b, Laura Serino c, Rosita De Paola c, Ann Holland d, Jennifer Louth d, Mary E. Ramsay b, Shamez N. Ladhani b, e, Ray Borrow a, dHighlights |
• | 4CMenB reduces disease due to strains with cross-reactive antigen variants. |
• | No increase in absolute numbers of cases due to poorly covered strains was observed. |
• | Further evidence of the importance of a booster for NadA-mediated protection. |
• | Further evidence for waning of pora-mediated immunity pre-booster. |
Abstract |
Objectives |
In 2015 the UK became the first country to implement the meningococcal B (MenB) vaccine, 4CMenB, into the national infant program. 4CMenB is expected to cover meningococci expressing sufficient levels of cross-reactive proteins. This study presents clonal complex, 4CMenB antigen genotyping, and 4CMenB coverage data for all English invasive MenB isolates from 2014/15 (1 year pre-vaccine) through 2017/18 and compares data from vaccinated and unvaccinated ≤3 year olds.
Methods |
Vaccine coverage of all invasive MenB isolates from 2014/15 to 2017/18 (n = 784) was analysed using the Meningococcal Antigen Typing System. Genotyping utilised the Meningococcus Genome Library.
Results |
Among ≤3 year olds, proportionally fewer cases in vaccinees (1, 2 or 3 doses) were associated with well-covered strains e.g. cc41/44 (20.5% versus 36.4%; P<0.01) and antigens e.g. PorA P1.4 (7.2% versus 17.3%; P = 0.02) or fHbp variant 1 peptides (44.6% vs 69.1%; P<0.01). Conversely, proportionally more cases in vaccinees were associated with poorly-covered strains e.g. cc213 (22.9% versus 9.6%; P<0.01) and antigens e.g. variant 2 or 3 fHbp peptides (54.2% versus 30.9%; P<0.01).
Conclusions |
4CMenB reduces disease due to strains with cross-reactive antigen variants. No increase in absolute numbers of cases due to poorly covered strains was observed in the study period.
Le texte complet de cet article est disponible en PDF.Key Words : Meningococcal disease, Serogroup B, 4CMenB, Meningococcal antigen typing system, MATS, Vaccine coverage, England
Plan
Vol 84 - N° 2
P. 136-144 - février 2022 Retour au numéro
Article précédent
- Prediction of mortality in Staphylococcus aureus bloodstream infection using quick Pitt bacteremia score
- Sarah E. Battle, Matthew Shuping, Sarah Withers, Julie A. Justo, P. Brandon Bookstaver, Majdi N. Al-Hasan
- Burden of influenza disease in children under 2 years of age hospitalized between 2011 and 2020 in France
- Célia Tillard, Emmanuel Chazard, Karine Faure, Stéphanie Bartolo, Alain Martinot, François Dubos
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?